Generic placeholder image

Central Nervous System Agents in Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 1871-5249
ISSN (Online): 1875-6166

Case Report

The Efficacy of Melanin Precursor QIAPI 1© Against Age-related Macular Degeneration (AMD): A Case Report

Author(s): Arturo S. Herrera, Narasimha M. Beeraka, Luis Fernando T. Solis, Liudmila M. Mikhaleva, Siva G. Somasundaram, Cecil E. Kirkland and Gjumrakch Aliev*

Volume 20, Issue 3, 2020

Page: [218 - 225] Pages: 8

DOI: 10.2174/1871524920666201109152951

open access plus

Abstract

Background: AMD is becoming one of the leading causes of blindness in older adults. The prevalence rate of the wet form of AMD has been increasing due to the lack of selective therapeutic modalities. Current therapeutic interventions such as drugs targeting VEGF, and VEGF receptors, laser coagulants delivered unsuccessful clinical outcomes in AMD patients. Hence, the cost-effective anti-oxidant therapeutic interventions like molecular hydrogen to protect retinal pigment epithelium (RPE) by mitigating oxidative stress may deliver effective clinical outcomes in AMD patients.

Methods: Female patients with late-stage AMD of age above 70 years were chosen for this case report. The patients were administered QIAPI1©, a melanin precursor via sublingual route and the photographs were obtained for left and right eye to depict the efficacy of QIAPI1© against the wet form of AMD.

Results: The administration of QIAPI1© extensively mitigated yellow-colored drusen accumulations in the retina, retinal edema, exudates, and hemorrhages in the right eye, but the effect was minimal in the case of left eye; the overall drusen accumulation was lesser than the first consultation.

Conclusion: Current case report has concluded the intrinsic effect of melanin in producing the molecular hydrogen and chemical energy across the retinal tissues by dissociating water molecules and dissipating the drusen accumulations, retinal edema, and hemorrhages in AMD patients. Our preliminary study reported the usage of QIAPI1© as a prospective therapeutic modality to mitigate the oxidative stress-mediated pathophysiology of the wet form of AMD.

Keywords: AMD, melanin, QIAPI1©, drusen accumulations, retinal pigment epithelium, oxidative stress, molecular hydrogen.

Graphical Abstract
[1]
Klein R, Klein BE, Linton KL. Prevalence of age-related maculopathy. The Beaver Dam Eye Study. Ophthalmology 1992; 99(6): 933-43.
[http://dx.doi.org/10.1016/S0161-6420(92)31871-8] [PMID: 1630784]
[2]
Mitchell P, Smith W, Attebo K, Wang JJ. Prevalence of age-related maculopathy in Australia. The Blue Mountains Eye Study. Ophthalmology 1995; 102(10): 1450-60.
[http://dx.doi.org/10.1016/S0161-6420(95)30846-9] [PMID: 9097791]
[3]
Vingerling JR, Dielemans I, Hofman A, et al. The prevalence of age-related maculopathy in the Rotterdam Study. Ophthalmology 1995; 102(2): 205-10.
[http://dx.doi.org/10.1016/S0161-6420(95)31034-2] [PMID: 7862408]
[4]
Evans JR. Risk factors for age-related macular degeneration. Prog Retin Eye Res 2001; 20(2): 227-53.
[http://dx.doi.org/10.1016/S1350-9462(00)00023-9] [PMID: 11173253]
[5]
Datta S, Cano M, Ebrahimi K, Wang L, Handa JT. The impact of oxidative stress and inflammation on RPE degeneration in non-neovascular AMD. Prog Retin Eye Res 2017; 60: 201-18.
[http://dx.doi.org/10.1016/j.preteyeres.2017.03.002] [PMID: 28336424]
[6]
Kevany BM, Palczewski K. Phagocytosis of retinal rod and cone photoreceptors. Physiology (Bethesda) 2010; 25(1): 8-15.
[http://dx.doi.org/10.1152/physiol.00038.2009] [PMID: 20134024]
[7]
Bellezza I. Oxidative stress in age-related macular degeneration: Nrf2 as therapeutic target. Front Pharmacol 2018; 9: 1280.
[http://dx.doi.org/10.3389/fphar.2018.01280] [PMID: 30455645]
[8]
Farboud B, Aotaki-Keen A, Miyata T, Hjelmeland LM, Handa JT. Development of a polyclonal antibody with broad epitope specificity for advanced glycation endproducts and localization of these epitopes in Bruch’s membrane of the aging eye. Mol Vis 1999; 5: 11.
[PMID: 10407062]
[9]
Crabb JW, Miyagi M, Gu X, et al. Drusen proteome analysis: an approach to the etiology of age-related macular degeneration. Proc Natl Acad Sci USA 2002; 99(23): 14682-7.
[http://dx.doi.org/10.1073/pnas.222551899] [PMID: 12391305]
[10]
Klaver CC, Wolfs RC, Vingerling JR, Hofman A, de Jong PT. Age-specific prevalence and causes of blindness and visual impairment in an older population: the Rotterdam Study. Arch Ophthalmol 1998; 116(5): 653-8.
[http://dx.doi.org/10.1001/archopht.116.5.653] [PMID: 9596502]
[11]
Snodderly DM, Auran JD, Delori FC. The macular pigment. II. Spatial distribution in primate retinas. Invest Ophthalmol Vis Sci 1984; 25(6): 674-85.
[PMID: 6724837]
[12]
Khachik F, Bernstein PS, Garland DL. Identification of lutein and zeaxanthin oxidation products in human and monkey retinas. Invest Ophthalmol Vis Sci 1997; 38(9): 1802-11.
[PMID: 9286269]
[13]
Bone RA, Landrum JT, Fernandez L, Tarsis SL. Analysis of the macular pigment by HPLC: Retinal distribution and age study. Invest Ophthalmol Vis Sci 1988; 29(6): 843-9.
[PMID: 3372161]
[14]
Handelman GJ, Dratz EA, Reay CC, van Kuijk JG. Carotenoids in the human macula and whole retina. Invest Ophthalmol Vis Sci 1988; 29(6): 850-5.
[PMID: 3372162]
[15]
Berendschot TT, Willemse-Assink JJ, Bastiaanse M, de Jong PT, van Norren D. Macular pigment and melanin in age-related maculopathy in a general population. Invest Ophthalmol Vis Sci 2002; 43(6): 1928-32.
[PMID: 12037001]
[16]
Pennington KL, DeAngelis MM. Epidemiology of age-related macular degeneration (AMD): associations with cardiovascular disease phenotypes and lipid factors. Eye Vis (Lond) 2016; 3: 34.
[http://dx.doi.org/10.1186/s40662-016-0063-5] [PMID: 28032115]
[17]
Hernández-Zimbrón LF, Zamora-Alvarado R, Velez-Montoya R, et al. Age-related macular degeneration: New paradigms for treatment and management of AMD. Oxid Cell Longev 2018.
[http://dx.doi.org/10.1155/2018/8374647]
[18]
Liu Y, Li R, Xie J, et al. Protective effect of hydrogen on sodium iodate-induced age-related macular degeneration in mice. Front Aging Neurosci 2018; 10: 389.
[http://dx.doi.org/10.3389/fnagi.2018.00389] [PMID: 30564112]
[19]
Holz FG, Schmitz-Valckenberg S, Fleckenstein M. Recent developments in the treatment of age-related macular degeneration. J Clin Invest 2014; 124(4): 1430-8.
[http://dx.doi.org/10.1172/JCI71029] [PMID: 24691477]
[20]
Rakoczy EP. Gene therapy for the long term treatment of wet AMD. Lancet 2017; 390(10089): 6-7.
[http://dx.doi.org/10.1016/S0140-6736(17)31262-X] [PMID: 28526492]
[21]
Wong WL, Su X, Li X, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: A systematic review and meta-analysis. Lancet Glob Health 2014; 2(2): e106-16.
[http://dx.doi.org/10.1016/S2214-109X(13)70145-1] [PMID: 25104651]
[22]
Ghasemi H, Pourakbari MS, Entezari M, Yarmohammadi ME. Association of age related macular degeneration and age related hearing impairment. J Ophthalmic Vis Res 2016; 11(1): 54-60.
[http://dx.doi.org/10.4103/2008-322X.180699] [PMID: 27195086]
[23]
Ames A III, Li Y-Y, Heher EC, Kimble CR. Energy metabolism of rabbit retina as related to function: High cost of Na+ transport. J Neurosci 1992; 12(3): 840-53.
[http://dx.doi.org/10.1523/JNEUROSCI.12-03-00840.1992] [PMID: 1312136]
[24]
Kahn HA, Leibowitz HM, Ganley JP, et al. The Framingham Eye Study. I. Outline and major prevalence findings. Am J Epidemiol 1977; 106(1): 17-32.
[http://dx.doi.org/10.1093/oxfordjournals.aje.a112428] [PMID: 879158]
[25]
Klein R, Davis MD, Magli YL, Segal P, Klein BE, Hubbard L. The Wisconsin age-related maculopathy grading system. Ophthalmology 1991; 98(7): 1128-34.
[http://dx.doi.org/10.1016/S0161-6420(91)32186-9] [PMID: 1843453]
[26]
Rosenfeld PJ, Brown DM, Heier JS, et al. MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355(14): 1419-31.
[http://dx.doi.org/10.1056/NEJMoa054481] [PMID: 17021318]
[27]
Schmidt-Erfurth U, Eldem B, Guymer R, et al. EXCITE Study Group Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study. Ophthalmology 2011; 118(5): 831-9.
[http://dx.doi.org/10.1016/j.ophtha.2010.09.004] [PMID: 21146229]
[28]
Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ. CATT Research Group Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011; 364(20): 1897-908.
[http://dx.doi.org/10.1056/NEJMoa1102673] [PMID: 21526923]
[29]
Gehrs KM, Jackson JR, Brown EN, Allikmets R, Hageman GS. Complement, age-related macular degeneration and a vision of the future. Arch Ophthalmol 2010; 128(3): 349-58.
[http://dx.doi.org/10.1001/archophthalmol.2010.18] [PMID: 20212207]
[30]
Herrera SA, del Carmen Arias Esparza M, Arias ESP, et al. Unsuspected intrinsic property of melanin to dissociate water can be used for the treatment of CNS diseases CNS Neurol Disord-Drug Targets (Formerly Current Drug Targets-CNS Neurological Disorders) 2016; 15: 135-40.
[http://dx.doi.org/10.2174/1871527315666160202122943]
[31]
Liu Y, Hong L, Wakamatsu K, et al. Comparison of structural and chemical properties of black and red human hair melanosomes. Photochem Photobiol 2005; 81(1): 135-44.
[http://dx.doi.org/10.1562/2004-08-03-RA-259.1] [PMID: 15504086]
[32]
Hu D-N, Savage HE, Roberts JE. Uveal melanocytes, ocular pigment epithelium, and Müller cells in culture: In vitro toxicology. Int J Toxicol 2002; 21(6): 465-72.
[http://dx.doi.org/10.1080/10915810290169891] [PMID: 12537643]
[33]
Aliev G, Solís-Herrera A, Li Y, et al. Human photosynthesis, the ultimate answer to the long term mystery of Kleiber’s law or E=M 3/4: Implication in the context of gerontology and neurodegenerative diseases. Open J Psychiatr 2013; 3: 408-21.
[34]
Hu D-N, McCormick SA, Yu G-P. Latitude and uveal melanoma. Ophthalmology 2008; 115(4): 757.
[http://dx.doi.org/10.1016/j.ophtha.2007.11.011] [PMID: 18387420]
[35]
Hu DN, Simon JD, Sarna T. Role of ocular melanin in ophthalmic physiology and pathology. Photochem Photobiol 2008; 84(3): 639-44.
[http://dx.doi.org/10.1111/j.1751-1097.2008.00316.x] [PMID: 18346089]
[36]
S Herrera A, del CA Esparza M, A Zamyatnin A, Aliev G. Beyond mitochondria, what would be the energy source of the cell? Central Nervous System Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry-Central Nervous System Agents) 2015; 15: 32-41.
[37]
Campochiaro PA. Retinal and choroidal neovascularization. J Cell Physiol 2000; 184(3): 301-10.
[http://dx.doi.org/10.1002/1097-4652(200009)184:3<301:AID-JCP3>3.0.CO;2-H] [PMID: 10911360]
[38]
Hageman GS, Luthert PJ, Chong NH, Johnson LV, Anderson DH, Mullins RF. An integrated hypothesis that considers drusen as biomarkers of immune-mediated processes at the RPE-Bruch’s membrane interface in aging and age-related macular degeneration. Prog Retin Eye Res 2001; 20(6): 705-32.
[http://dx.doi.org/10.1016/S1350-9462(01)00010-6] [PMID: 11587915]
[39]
Schmidt SY, Peisch RD. Melanin concentration in normal human retinal pigment epithelium. Regional variation and age-related reduction. Invest Ophthalmol Vis Sci 1986; 27(7): 1063-7.
[PMID: 3721785]
[40]
Sarna T. Properties and function of the ocular melanin--a photobiophysical view. J Photochem Photobiol B 1992; 12(3): 215-58.
[http://dx.doi.org/10.1016/1011-1344(92)85027-R] [PMID: 1635010]
[41]
Fazelat A, Bahrani H, Buzney S, Lashkari K, Weiter JJ. Autoimmunity and age-related macular degeneration: A review of the literature. Semin Ophthalmol 2011; 26(4-5): 304-11.
[http://dx.doi.org/10.3109/08820538.2011.588666]]
[42]
Telander DG. Inflammation and age-related macular degeneration (AMD). In:Seminars in ophthalmology Taylor Francis: USA,. 2011; pp. 192-7.
[43]
Schneck ME, Lott LA, Haegerstrom-Portnoy G, Brabyn JA. Association between hearing and vision impairments in older adults. Ophthalmic Physiol Opt 2012; 32(1): 45-52.
[http://dx.doi.org/10.1111/j.1475-1313.2011.00876.x] [PMID: 21999724]
[44]
Kaltenbach JA. Tinnitus: Models and mechanisms. Hear Res 2011; 276(1-2): 52-60.
[http://dx.doi.org/10.1016/j.heares.2010.12.003] [PMID: 21146597]
[45]
Herrera AS, Arias PES, Del Carmen Arias Esparza M, et al. The Long-term effect of medically enhancing melanin intrinsic bioenergetics capacity in prematurity. Curr Genomics 2020; 2020: 21.
[46]
Herrera AS. A Esparza MdC, Arias PE, et al. The role of melanin to dissociate oxygen from water to treat retinopathy of prematurity. Central Nervous Sys Agents Med Chem (Formerly Current Medicinal Chemistry-Central Nervous System Agents) 2019; 19: 215-2.
[47]
Herrera AS, del Carmen Arias Esparza M, Solís Arias PE, et al. Unsuspected intrinsic property of melanin to dissociate water can be used for the treatment of CNS diseases. CNS Neurol Disord Drug Targets 2016; 15(2): 135-40.
[http://dx.doi.org/10.2174/1871527315666160202122943] [PMID: 26831264]
[48]
Solís-Herrera A. M Ashraf G, del CA Esparza M, et al. Biological activities of QIAPI 1 as a melanin precursor and its therapeutic effects in wistar rats exposed to arsenic poisoning. Central Nervous Sys Agents Med Chem (Formerly Current Medicinal Chemistry- Central Nervous System Agents) 2015; 15: 99-108.
[49]
Boulton ME. Studying melanin and lipofuscin in RPE cell culture models. Exp Eye Res 2014; 126: 61-7.
[http://dx.doi.org/10.1016/j.exer.2014.01.016] [PMID: 25152361]
[50]
Zhang W, Ito Y, Berlin E, Roberts R, Berkowitz BA. Role of hypoxia during normal retinal vessel development and in experimental retinopathy of prematurity. Invest Ophthalmol Vis Sci 2003; 44(7): 3119-23.
[http://dx.doi.org/10.1167/iovs.02-1122] [PMID: 12824260]
[51]
Holmström G, Tornqvist K, Al-Hawasi A, Nilsson Å, Wallin A, Hellström A. Increased frequency of retinopathy of prematurity over the last decade and significant regional differences. Acta ophthalmologica 2018; 96(2): 142-8.
[http://dx.doi.org/10.1111/aos.13549] [PMID: 29068172]
[52]
Blencowe H, Moxon S, Gilbert C. Update on blindness due to retinopathy of prematurity globally and in India. Indian Pediatr 2016; 53(Suppl. 2): S89-92.
[PMID: 27915313]
[53]
Quinn GE, Dobson V, Kivlin J, et al. Cryotherapy for Retinopathy of Prematurity Cooperative Group Prevalence of myopia between 3 months and 5 1/2 years in preterm infants with and without retinopathy of prematurity. Ophthalmology 1998; 105(7): 1292-300.
[http://dx.doi.org/10.1016/S0161-6420(98)97036-1] [PMID: 9663236]
[54]
Abisso T, Adzavon Y, Zhao P, Zhang X, Liu M, Ma X. Current progress in molecular hydrogen medication: Protective and therapeutic uses of hydrogen against different disease scenarios. Intern Med 2020; 10: 314.
[55]
Tian L, Zhang L, Xia F, An J, Sugita Y, Zhang Z. Hydrogen-rich saline ameliorates the retina against light-induced damage in rats. Med Gas Res 2013; 3(1): 19.
[http://dx.doi.org/10.1186/2045-9912-3-19] [PMID: 24004679]
[56]
Liu Y, Liu W, Sun X, et al. Hydrogen saline offers neuroprotection by reducing oxidative stress in a focal cerebral ischemia-reperfusion rat model. Med Gas Res 2011; 1(1): 15.
[http://dx.doi.org/10.1186/2045-9912-1-15] [PMID: 22146222]
[57]
Chau FY, Wallace D, Vajaranant T, et al. Osteogenesis imperfecta and the eye. Osteogen Imperfect 2014; 31: 289-303.
[http://dx.doi.org/10.1016/B978-0-12-397165-4.00031-9]
[58]
Schmidl D, Garhöfer G, Schmetterer L. Nutritional supplements in age-related macular degeneration. Acta Ophthalmol 2015; 93(2): 105-21.
[http://dx.doi.org/10.1111/aos.12650] [PMID: 25586104]
[59]
Tan JS, Wang JJ, Flood V, Rochtchina E, Smith W, Mitchell P. Dietary antioxidants and the long-term incidence of age-related macular degeneration: The Blue Mountains Eye Study. Ophthalmology 2008; 115(2): 334-41.
[http://dx.doi.org/10.1016/j.ophtha.2007.03.083] [PMID: 17664009]
[60]
Miller JW, Le Couter J, Strauss EC, Ferrara N. Vascular endothelial growth factor a in intraocular vascular disease. Ophthalmology 2013; 120(1): 106-14.
[http://dx.doi.org/10.1016/j.ophtha.2012.07.038] [PMID: 23031671]

© 2022 Bentham Science Publishers | Privacy Policy